-       Report 
- September 2025
-  124 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- August 2022
-  115 Pages 
- Global 
   From       €4004EUR$4,500USD£3,525GBP 
            -       Report 
- January 2024
-  250 Pages 
- Global 
   From       €5660EUR$6,360USD£4,982GBP 
      €7074EUR$7,950USD£6,227GBP 
          -       Report 
- October 2018
-  19 Pages 
- Global 
   From       €8899EUR$10,000USD£7,833GBP 
             Tracleer is a cardiovascular drug used to treat pulmonary arterial hypertension (PAH). It is a type of endothelin receptor antagonist (ERA) that works by blocking the action of endothelin, a substance in the body that can cause the blood vessels in the lungs to narrow. This narrowing can lead to high blood pressure in the lungs, which can cause shortness of breath, fatigue, and other symptoms. Tracleer is used to reduce the symptoms of PAH and improve the patient's quality of life.
Tracleer is    marketed by Actelion Pharmaceuticals, a Swiss biopharmaceutical company. Other companies in the market include Gilead Sciences, GlaxoSmithKline, and Bayer. Show Less   Read more